3632 results for «210»
3632 results
TMVR challenges
27 Nov 2022 – From PCR London Valves 2022
Challenges in this session of PCR LV 2022 include hybrid valve implantation for mitral annular calcification, transcatheter double-valve implantation complicated by mitral bioprosthesis migration, and transcatheter transseptal mitral valve implantation. Watch now to find out more!
TRISCEND, ACURATE neo2, the LuX-Valve System: Top Late-Breaking Trials from PCR London Vaves 2022
27 Nov 2022 – From PCR London Valves 2022
Discover a selection of PCR London Valves 2022 Late-Breaking Trial submissions and learn more about the latest evidence evidence concerning new transcatheter valve devices, emerging innovative devices as well as highlighted content from the EuroIntervention journal.
CLASP II TR, TriBAND, bRIGHT: Late-Breaking Trials on tricuspid intervention
27 Nov 2022 – From PCR London Valves 2022
Discover a selection of PCR London Valves 2022 Late-Breaking Trial submissions in this session: the CLASP II TR on transcatheter tricuspid valve repair, the TriBAND study one-year outcomes on transcatheter tricuspid annular reduction, and the bRIGHT trial on real-world outcomes for TEER.
Rapid-fire abstracts: session 3
27 Nov 2022 – From PCR London Valves 2022
Everything you need to know about the OPERA-TAVI registry, the UK TAVI registry, the TAVI-COMIC study, or the external validation of the TRI-SCORE in patients undergoing isolated tricuspid valve surgery, among others, can be found in this session of PCR LV 2022.
TAVI: Late-Breaking Trials and Innovations
27 Nov 2022 – From PCR London Valves 2022
Consult this session to discover a selection of PCR London Valves 2022 Late-Breaking Trial submissions, and learn more about the early safety and performance of the Vienna TAVI system, the new-generation transcatheter aortic valve platforms performance in native pure aortic regurgitation, and more!
Rapid-fire abstracts: session 4
27 Nov 2022 – From PCR London Valves 2022
In this PCR LV 2022 session dedicated to TAVI, take advantage of the 7 abstracts to learn more about the impact of TAVI for pure regurgitation on the severity of concomitant mitral regurgitation, the deformation of transcatheter heart valve and haemodynamics after aortic ViV, and much...
Mitral valve in mitral annular calcification (MAC) - Recorded case
27 Nov 2022 – From PCR London Valves 2022
A 53-year-old male with a history of SAVR (Perimount 23) 10 years ago and chest radiotherapy (lymphoma) presents a severe mitral stenosis (MAC) with preserved LV function and impaired RV function.
On sentinel cerebral protection, the operators perform a transseptal puncture with electrifying a non-stiff guide wire,...
The multidisciplinary structural heart team - How do we include the patient
27 Nov 2022 – From PCR London Valves 2022
Consult this session on the multidisciplinary structural heart team to learn more about the evolving role of the team and how this affects decision making, to discover why patient advocacy and partnership is vital within the team, as well as to identify potential barriers and enablers of the future...
EuroIntervention Case Reports has launched!
19 May 2026
The first and only peer-reviewed case report journal dedicated entirely to interventional cardiovascular medicine: EuroIntervention Case Reports.
MATTERHORN - Transcatheter versus surgical mitral valve repair in patients with heart failure and secondary mitral regurgitation
01 Sep 2024
Yohei Ohno provides his takeaways from the results of the MATTERHORN trial presented by Volker Rudolph at the ESC Congress 2024 in London.
Author
Protein and exercise to reverse frailty in older men and women undergoing transcatheter aortic valve replacement: The PERFORM-TAVR Trial
08 Apr 2024
Panos Xaplanteris provides his take on the results of PERFORM-TAVR presented by Jonathan Afilalo at ACC.24 in Atlanta.
Author
ALL-RISE: A large-scale, global randomized trial of coronary physiology derived from conventional angiography compared with an invasive pressure wire-based approach to guide PCI
28 Mar 2026
Mirvat Al Asnag provides her take on the ALL-RISE randomised trial presented by Ajay J. Kirtane at ACC.26 in New Orleans.
Author
